sab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.
Company profile
Ticker
SABS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Big Cypress Acquisition Corp.
SEC CIK
Corporate docs
IRS number
853899721
SABS stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
15 Apr 24
8-K
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
29 Mar 24
8-K
Entry into a Material Definitive Agreement
8 Mar 24
S-8
Registration of securities for employees
23 Feb 24
8-K
SAB Biotherapeutics Announces Executive Leadership Change
2 Feb 24
8-K
Entry into a Material Definitive Agreement
26 Jan 24
424B5
Prospectus supplement for primary offering
26 Jan 24
8-K
Other Events
25 Jan 24
8-K
Regulation FD Disclosure
19 Jan 24
8-K
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
3 Jan 24
Latest ownership filings
4
Alexandra Kropotova
23 Feb 24
4
Eddie Joe Sullivan
23 Feb 24
4
Christoph Lawrence Bausch
23 Feb 24
4
Michael King
23 Feb 24
4
Samuel J Reich
23 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
Radcliffe Capital Management, L.P.
14 Feb 24
4
Eddie Joe Sullivan
8 Dec 23
SC 13G
BIOTECHNOLOGY VALUE FUND L P
4 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.43 mm | 2.43 mm | 2.43 mm | 2.43 mm | 2.43 mm | 2.43 mm |
Cash burn (monthly) | 1.78 mm | 492.23 k | 1.77 mm | 2.29 mm | 1.72 mm | 1.10 mm |
Cash used (since last report) | 11.91 mm | 3.29 mm | 11.86 mm | 15.29 mm | 11.51 mm | 7.37 mm |
Cash remaining | -9.49 mm | -863.79 k | -9.43 mm | -12.87 mm | -9.09 mm | -4.94 mm |
Runway (months of cash) | -5.3 | -1.8 | -5.3 | -5.6 | -5.3 | -4.5 |
Institutional ownership, Q3 2023
22.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 7 |
Closed positions | 34 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 61.50 mm |
Total shares | 2.07 mm |
Total puts | 0.00 |
Total calls | 62.50 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Big Cypress | 756.30 k | $1.45 mm |
LMR Partners | 539.59 k | $37.77 mm |
Shaolin Capital Management | 465.72 k | $33.00 k |
MS Morgan Stanley | 148.94 k | $10.43 mm |
Yakira Capital Management | 108.49 k | $8.14 mm |
Walleye Capital | 23.26 k | $1.63 mm |
Walleye Trading | 15.51 k | $1.09 mm |
Wolverine Asset Management | 12.77 k | $893.00 k |
GWM Advisors | 1.07 k | $75.00 k |
Tower Research Capital | 48.00 | $4.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Dec 23 | Eddie Joe Sullivan | Common Stock | Buy | Acquire P | No | No | 0.88 | 1,740 | 1.53 k | 5,232,304 |
30 Nov 23 | Michael King | Common Stock | Buy | Acquire P | No | No | 0.9 | 5,000 | 4.50 k | 5,000 |
29 Nov 23 | Samuel J Reich | Common Stock | Buy | Acquire P | No | No | 0.8947 | 11,000 | 9.84 k | 219,001 |
24 Nov 23 | Helen K. Ellias | Common Stock | Option exercise | Acquire M | Yes | No | 0 | 2,857,142 | 0.00 | 2,857,142 |
24 Nov 23 | Helen K. Ellias | Series A-1 Convertible Preferred Stock Common Stock or Series A-2 Convertible Preferred Stock | Option exercise | Dispose M | Yes | No | 1000 | 1,800 | 1.80 mm | 0 |
24 Nov 23 | Andrew Moin | Common Stock | Option exercise | Acquire M | Yes | No | 0 | 4,584,571 | 0.00 | 4,584,571 |
24 Nov 23 | Andrew Moin | Series A-2 Convertible Preferred Stock Common Stock | Option exercise | Acquire M | Yes | No | 1000 | 28,380 | 28.38 mm | 28,380 |
24 Nov 23 | Andrew Moin | Series A-1 Convertible Preferred Stock Common Stock or Series A-2 Convertible Preferred Stock | Option exercise | Dispose M | Yes | No | 1000 | 31,269 | 31.27 mm | 0 |
News
HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $6 Price Target
16 Apr 24
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $25 Price Target
16 Apr 24
Chardan Capital Maintains Buy on SAB Biotherapeutics, Adjusts Price Target To $25 (reverse stock split 1:10)
2 Apr 24
HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $6
2 Apr 24
SAB Biotherapeutics Announces Clinical Partnership With Naval Medical Research Center To Advance Potential Influenza Treatment
25 Mar 24
Press releases
SAB Biotherapeutics Provides SAB-142 Trial Update
16 Apr 24
SAB Biotherapeutics to Present at INNODIA Annual Meeting
8 Apr 24
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
4 Apr 24
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
29 Mar 24
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
25 Mar 24